Drug intelligence / Profile preview

Cornus officinalis triterpenoid tablet

Development stage
Unknown
Lead developer
Cinkate
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

Cornus officinalis triterpenoid tablet is a botanical drug candidate developed by Suzhou Changzheng-Xinkai Pharmaceutical for the treatment of type 2 diabetes mellitus. The drug is a tablet formulation containing the total triterpenoid fraction extracted from the fruit of *Cornus officinalis* (Shan Zhu Yu), a plant widely used in traditional Chinese medicine. Triterpenoids from this species, including compounds like ursolic acid and oleanolic acid, have been investigated for their ability to regulate glucose metabolism and improve insulin sensitivity. Preclinical research suggests these effects may be mediated through the inhibition of protein tyrosine phosphatase 1B (PTP1B) and the activation of the AMPK signaling pathway. The drug has undergone Phase 1 clinical evaluation in China to assess its safety, tolerability, and pharmacokinetics in healthy volunteers, intended to support further development for patients with early-stage, mild type 2 diabetes.

Other names
Cornus officinalis total triterpenoid tabletsShan Zhu Yu Zong San Tie Pian
02

Targets

PTPN1 (Protein tyrosine phosphatase 1B)

Beyond the preview

Go deeper on Cornus officinalis triterpenoid tablet.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cornus officinalis triterpenoid tablet.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call